VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP POWDER FOR SOLUTION

Երկիր: Կանադա

Լեզու: անգլերեն

Աղբյուրը: Health Canada

Ակտիվ բաղադրիչ:

VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE)

Հասանելի է:

HIKMA CANADA LIMITED

ATC կոդը:

J01XA01

INN (Միջազգային անվանումը):

VANCOMYCIN

Դոզան:

10G

Դեղագործական ձեւ:

POWDER FOR SOLUTION

Կազմը:

VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE) 10G

Կառավարման երթուղին:

INTRAVENOUS

Միավորները փաթեթում:

100

Ռեկվիզորի տեսակը:

Prescription

Ապրանքի ամփոփագիր:

Active ingredient group (AIG) number: 0131315004; AHFS:

Լիազորման կարգավիճակը:

APPROVED

Հաստատման ամսաթիվը:

2022-09-26

Ապրանքի հատկությունները

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP
5 g and 10 g of vancomycin (as vancomycin hydrochloride) per vial
Sterile lyophilized
powder for solution
ANTIBIOTIC
HIKMA CANADA LTD.
Date of Preparation:
Avebury Road, Suite 804 September 15, 2022
Mississauga, ON
L5R 3P9, Canada
Control No.: 249363
Vancomycin Hydrochloride for Injection, USP
–
Product Monograph
Page 2 of 32
PR
VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP
ANTIBIOTIC
ACTIONS
The inhibition
of cell wall synthesis has been shown by _ in vitro _studies to be
responsible for the
bactericidal action of vancomycin against many gram-positive bacteria.
There is also evidence that
RNA synthesis is selectively
inhibited
and the permeability
of the cell membrane is altered by
vancomycin.
INDICATIONS AND CLINICAL USE
Vancomycin
Hydrochloride
for Injection,
USP is indicated
in
the therapy of severe or life -
threatening staphylococcal infections in patients who cannot receive
or have failed to respond to
the penicillins
or cephalosporins,
or who have infections
with staphylococci
resistant to other
antibiotics,
including methicillin.
To
reduce
the
development
of
drug-resistant
bacteria
and
maintain
the
effectiveness
of
Vancomycin
Hydrochloride
for
Injection,
USP and
other
antibacterial
drugs,
Vancomycin
Hydrochloride for Injection USP should be used only to treat
infections that are proven or strongly
suspected to be caused by susceptible bacteria. When culture and
susceptibility
information
are
available, they should be considered in selecting or modifying
antibacterial therapy. In the absence
of such data, local epidemiology and susceptibility patterns may
contribute to the empiric selection
of therapy.
In the treatment of staphylococcal endocarditis, vancomycin has been
used successfully alone.
In other infections due to staphylococci, including
osteomyelitis,
pneumonia, septicemia and soft-
tissue infections, vancomycin's effectiveness has been documented.
Antibiotics are used as
Vancomycin Hydrochlo